The government will provide free entry, in perpetuity, to everyone visiting the proposed new Holocaust Memorial and Learning Centre, Communities Secretary Robert Jenrick announced today (28 January 2021).

Giving universal free access to the memorial puts the UK on the same footing as the most important monuments and museums and will reassure Holocaust survivors their testimony will be freely available to all when they are no longer able to tell the story themselves, forever.

The Memorial, which is planned to be built next to Parliament in Victoria Tower Gardens, will be the focal point for national remembrance of the six million Jewish men, women and children murdered in the Holocaust and all other victims of Nazi persecution.

The learning centre will be a world-class facility, giving visitors powerful and engaging experiences to learn about the Holocaust and subsequent genocides through a variety of mediums including historic photographs, film footage and audio recordings.

Government support will supplement funds raised from visitor donations and other charitable contributions to cover the running costs of the Memorial and Learning Centre which, subject to planning permission, is expected to open in 2024. The government has already announced that it will contribute up to £75 million towards construction costs, to be supplemented by £25 million from charitable donations.

The Communities Secretary also announced a further £25,000 funding to support the work the Wiener Library does in using its archive to bring closure to families who lost loved ones during the Holocaust.

Communities Secretary Rt Hon Robert Jenrick MP said:

Free entry, in perpetuity, to the proposed UK Holocaust Memorial and Learning Centre will mean that there are no barriers to people commemorating and learning about the evils of the Holocaust and is keeping with our national tradition of free entry to monuments and museums of great national significance.

As first-hand testimony from survivors becomes rarer and rarer, it is incumbent on all of us to be their witnesses. The Memorial will serve as a continual reminder to us all of why we need to make a stand against antisemitism, racism and hatred, whenever and wherever we find it – something that this government will always do.

Ed Balls and Lord Eric Pickles, Co-Chairs of the UK Holocaust Memorial Foundation, said:

This is the clearest demonstration of the Government’s commitment to addressing Holocaust Remembrance.  Free access will widen the visitor base and enable the centre to extend its message and work to a greater range of people.  The centre will work closely with other institutions, both national and international, to tackle Holocaust denial and Antisemitism.

Marie van der Zyl, Board of Deputies of British Jews President, said:

We welcome the news that entry to the proposed Holocaust Memorial and Learning Centre will be free to all visitors. We thank the government and the Secretary of State for this important announcement.

UK and international visitors will now have the opportunity to discover the truth about the Shoah, genocide and the dangerous places to which racism leads.

We hope this will increase understanding; help stop the lies and falsehoods surrounding this terrible period; and enable us all to confront prejudice wherever it is found.

Karen Pollock CBE, Chief Executive, Holocaust Educational Trust, said:

The Holocaust Memorial and Learning Centre will do immeasurable good for Holocaust education and remembrance in this country and I am delighted that it has been confirmed that this important resource will be accessible to all. We must ensure that the horrors of the Holocaust are never forgotten, and that its lessons are learnt for generations to come.

Sir Ben Helfgott MBE, Holocaust survivor, said:

The Holocaust Memorial and Learning Centre will ensure that the memory of those who perished in the Holocaust are never forgotten and that the testimonies of those who survived are protected and remembered. These are fundamental to conveying the lessons of tolerance and understanding.

• Over 167,600 volunteers tested in England between 6 and 22 of January 2021 as part of one of the most significant COVID-19 studies

• Final findings from Imperial College London and Ipsos MORI show infections remained very high throughout this period with 1 in 64 people infected

• Everyone must continue to stay at home, not have contact with others unless absolutely necessary and follow the rules to protect the NHS and save lives

The final findings from the eighth report of REACT, one of the country’s largest studies into COVID-19 infections in England, have been published today by Imperial College London and Ipsos MORI.

The latest REACT study provides a snapshot of the levels of infection in the general population between 6 and 22 January. The findings show infections in England have flattened but are at the highest level recorded by a REACT study, with the indication of a decline at the end of the reporting period.

The NHS is under significant pressure in England with over 37,000 people in hospital with the virus, twice as many as the first peak in April. 4,076 people are on ventilators, more than at any time in the pandemic. Everyone must play their part by staying at home to help reduce infections, protect the NHS and save lives.

Levels of infections varied across the regions and was highest in London, with 1 in 35 people infected, and highest nationally among those aged 18 to 24.

The main findings from the eighth REACT study for the period 6 to 22 January show:

• national prevalence was 1.57%, or 157 per 10,000 people infected
• national R is estimated at 0.98 with a range of 0.92 to 1.04
• regional prevalence was highest in London at 2.83%
• East of England at 1.78%
• West Midlands at 1.66%
• South East at 1.61%
• North West at 1.38%
• North East at 1.22%
• East Midlands at 1.16%
• Yorkshire and the Humber 0.80%
• South West at 0.87%
• prevalence increased nationally in all adult age groups and was highest in 18 to 24 year olds at 2.44%. Prevalence in the over 65s is 0.93%
• large household size, living in a deprived neighbourhood, and black and Asian ethnicity were more likely to test positive compared to smaller households, less deprived neighbourhoods and other ethnicities
• healthcare and care home workers, and other key workers were more likely to test positive compared to other workers

While the levels of infections are lower in Yorkshire and the Humber and the South West compared to other regions, they are still high.

Health and Social Care Secretary Matt Hancock said:

These findings are a stark reminder of the need to remain vigilant.

Infection rates this high will continue to put a strain on our NHS and add to the significant pressures dedicated health and care staff are already facing.

We must bring infections right down so I urge everyone to play their part to help save lives. You must stay at home unless absolutely necessary, follow social distancing rules and minimise contact with others.

Professor Paul Elliott, director of the programme at Imperial, said:

The number of people infected with the virus is at the highest level that we’ve recorded since we began testing last May.

We’re not seeing the sharp drop in infections that happened under the first lockdown and if infections aren’t brought down significantly, hospitals won’t be able to cope with the number of people that need critical care. We all need to stay at home wherever possible and help bring the virus under control and protect our already over-stretched health system.

While the vaccine programme continues to expand to protect as many people as possible, with over 6.8 million people vaccinated, we do not know whether being vaccinated stops someone from passing the virus on to others. It will also be some time before the impact of the vaccination programme reduces pressures on hospitals.

It is critical everyone continues to follow the rules, stays at home, reduces contact with others and maintains social distancing – remembering hands, face, space.

Kelly Beaver, Managing Director – Public Affairs at Ipsos MORI, said:

In the latest REACT snapshot across round 8 we continue to see very high levels of COVID-19 at a national level, which continues to be worrying. While we do see the suggestion of a downturn in the last few days of the study, which is encouraging, this is only tentative.

REACT continues to provide a powerful look across England at prevalence and spread of the pandemic and I thank all of the over 160,000 people who have taken part in this round for helping us provide this insight to government.

This report is the latest from the REACT study which was commissioned by the Department of Health and Social Care (DHSC) and carried out by a world-class team of scientists, clinicians and researchers at Imperial College London, Imperial College Healthcare NHS Trust and Ipsos MORI.

Over 167,000 randomly selected people over the age of 5 from across England volunteered to provide nose and throat swabs for this REACT report. These were tested for antigens indicating the presence of the virus to show whether someone is currently infected with COVID-19.

The study does not go out to the same participants in each round but selects new, randomly selected participants each time.

By randomly selecting participants, the study captures both those who display symptoms and those who do not, providing a greater insight into the levels of infection across the country. REACT does not run continuously but provides a timely two-week snapshot of prevalence in England at that specific time.

In line with government guidance those with positive test results and their household will be asked to self-isolate and referred to NHS Test and Trace for contact tracing.

The pre-print report embargoed to 0.01 Thursday 28 January 2020 can be downloaded here (Claim ID: ZBDHaZPdKkgKRtpB, claim passcode: 6KcEg43cRevfpKEn)

See more information on the Real-time Assessment of Community Transmission (REACT) programme of work.

This study falls under pillar 4 of the COVID-19 National Testing Programme, which focuses on mass surveillance in the general population.

The report was commissioned by DHSC and carried out by a world-class team of scientists, clinicians and researchers at Imperial College London, Imperial College Healthcare NHS Trust and Ipsos MORI.

See more information on the Real-time Assessment of Community Transmission (REACT) programme of work.

This follows a multi-million-pound joint investment in the facility by the UK government last year as part of an agreement in principle to secure early access to Valneva’s vaccine by the end of 2021. 60 million doses have already been secured for the UK, with an option to acquire a further 130 million if the vaccine is proven to be safe, effective and suitable.

This investment will now support 100 new highly-skilled jobs for scientists and technicians at the Livingston facility – doubling the workforce, putting Scotland at the forefront of the UK’s fight against COVID-19, and boosting the UK’s resilience in dealing with current and future pandemics by establishing a permanent vaccine manufacturing base.

Valneva’s coronavirus vaccine candidate is currently in phase I/II trials and will still need to meet the necessary safety and effectiveness standards and receive regulatory approval before it is rolled out at the end of the year. However, if it is approved, manufacturing at risk now will mean that the UK can roll the vaccine out across the country quicker.

Business Secretary Kwasi Kwarteng said:

Thanks to the UK Vaccine Taskforce, we have ordered up to 60 million jabs of Valneva’s promising vaccine if it proves to be safe, effective and suitable in its clinical trials this year.

By starting manufacturing, we will have a running start at rolling these out as quickly as possible to protect the British public if it receives regulatory approval.

This facility in Scotland, backed by millions from the Government, will help us beat coronavirus and boost our resilience against future pandemics.

The new facility establishes a permanent UK capability to manufacture inactivated viral vaccines – one of the most proven, widely used types which is also used for flu, polio and rabies jabs.

If the vaccine proves successful and receives regulatory approval following a rigorous assessment of available data, the Livingston facility will have the capacity to produce up to 250 million doses annually for shipment across the UK and around the world.

Scottish Secretary, Alister Jack said:

It’s incredibly exciting that a potential new COVID-19 vaccine will be manufactured right here in Scotland, at the Valneva plant in Livingston.

This big step forward is a testament to the talent and hard work of all the Valneva staff who have worked so far to get to this stage.

The UK government has invested millions into developing the Valneva vaccine, which is also supporting hundreds of highly skilled jobs in Scotland.

Chief Executive Officer of Valneva Thomas Lingelbach said:

We are extremely pleased to have achieved these 2 important milestones in such a short period of time. Our team in Scotland have done an amazing job to get manufacturing started so quickly.

I would like to thank the UK Vaccines Taskforce and National Institute for Health Research who have played vital roles in the rapid recruitment and enrolment of the volunteers for the clinical study. We believe that our vaccine, assuming successful development, can make a major contribution in the UK and beyond.

UK Health Secretary Matt Hancock said:

We’ve already secured 60 million doses of the Valneva vaccine which, if approved, will be another vital tool in our fight against this virus. ​> The start of manufacturing in West Lothian today puts Scottish expertise right at the heart of the UK vaccine programme.

Set to deliver millions more jabs across all four nations, this is yet another fantastic example of the strength of our Union, as we work together as one United Kingdom to tackle the virus.

Interim Chair of the UK government’s Vaccines Taskforce Clive Dix said:

I am thrilled that manufacturing has begun in Livingston as a result of the excellent work being done by Valneva in conjunction with the Vaccines Taskforce.

If approved this new vaccine will be a crucial part of our efforts to tackle coronavirus – not just in the UK but around the world.

Through the Vaccines Taskforce, the UK has secured early access to 367 million doses of seven of the most promising vaccines so far. To date, the UK government has invested over £230 million into manufacturing a successful vaccine.

The UK was the first country in the world to procure, authorise and then deploy both the Oxford/AstraZeneca and Pfizer/BioNTech vaccines.

Production of the Oxford University/AstraZeneca vaccine started last autumn where the bulk of the vaccine for the UK is being made in Oxfordshire and Staffordshire, with filling into vials taking place in North Wales.

In total, more than 7.1 million people across the UK have now had a least one dose of the vaccine.